 COPENHAGEN, Denmark, Aug. 12, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the second quarter 2021 financial results and provided an operational update. 